Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Key approvals and fast-track designations for Insmed, Alto Neuroscience, and Corcept Therapeutics boost investor confidence in the industry's regulatory landscape.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
GM, Ford, and Stellantis shares climb on news of potential tariff exemptions for U.S. vehicles, signaling a policy shift.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
The bank projects a near-term price target of $135,000 for Bitcoin, citing heavy ETF inflows and a break from historical post-halving patterns.